Voravutinon V
Department of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
J Med Assoc Thai. 1993 Jul;76(7):388-93.
Sixty-four patients with clinically and mycologically diagnosed tinea corporis and tinea cruris were randomly allocated to receive either 250 mg of oral terbinafine once daily or 500 mg of griseofulvin once daily for 2 wks. Patients in each group were well matched for age, gender, clinical features and type of dermatophytes. Clinical and mycological control tests (KOH wet mount and culture) were performed before treatment, at the end of treatment and 4 wks after stopping treatment. In the majority of cases, the infecting agent was identified as Trichophyton rubrum (53/64). The remainder comprised Trichophyton mentagrophytes (8/64) and Epidermophyton floccosum (3/64). After 2 wks of therapy, there was no significant difference in mycological response in the terbinafine group (90.3%) and griseofulvin group (80.7%). The clinical response in both groups was the same. At 6 wks' follow-up, the mycological cure in terbinafine and griseofulvin group was 87.1 and 54.8 per cent, respectively (P < 0.05). The clinical response of the terbinafine group was also significantly higher than in the griseofulvin group. A higher relapse rate was observed in the griseofulvin group than in the terbinafine group. No serious side effects were reported in either group. The result showed that oral terbinafine was more effective than oral griseofulvin in the treatment of tinea corporis or tinea cruris.
64例临床和真菌学诊断为体癣和股癣的患者被随机分配，分别每日口服250mg特比萘芬或每日口服500mg灰黄霉素，疗程2周。每组患者在年龄、性别、临床特征和皮肤癣菌类型方面匹配良好。在治疗前、治疗结束时及停药后4周进行临床和真菌学对照试验（KOH湿片法和培养）。在大多数病例中，感染病原体被鉴定为红色毛癣菌（53/64）。其余包括须癣毛癣菌（8/64）和絮状表皮癣菌（3/64）。治疗2周后，特比萘芬组（90.3%）和灰黄霉素组（80.7%）的真菌学反应无显著差异。两组的临床反应相同。在6周随访时，特比萘芬组和灰黄霉素组的真菌学治愈率分别为87.1%和54.8%（P<0.05）。特比萘芬组的临床反应也显著高于灰黄霉素组。灰黄霉素组的复发率高于特比萘芬组。两组均未报告严重副作用。结果表明，口服特比萘芬治疗体癣或股癣比口服灰黄霉素更有效。
